Rocket Pharmaceuticals · 7 hours ago
Senior Manager, Investor Relations & Corporate Communications
Maximize your interview chances
BiotechnologyGenetics
Insider Connection @Rocket Pharmaceuticals
Get 3x more responses when you reach out via email instead of LinkedIn.
Responsibilities
Draft, edit and coordinate the release of corporate presentations, investor presentations, press releases, and internal memos.
Support all aspects of quarterly earnings release including preparation of earnings materials and any investor webcasts.
Organize logistics and support the company’s participation in investor and analyst events, such as conferences, meetings, and non-deal roadshows.
Help Manage media, journalist, and investor inquiries.
Create and manage of all IR core materials including review and approval of corporate presentations, press releases, conference call scripts, and documents
Provide practical and meaningful Investor Relations support to management, including counseling and advising executives regarding investor events
Ensure timely input, participation, and internal alignment in IR strategies and activities
Collaborate closely with Corporate Communications to ensure a consistent message on branding and strategy
Provide ongoing public and media relations support including drafting social posts, holding statements, Q&A documents, etc.
Assist with media monitoring and summarizing analyst research reports.
Support internal company meetings and initiatives including global town halls and patient advocacy events.
Laise with website vendors to manage content updates.
Track all analyst models and consensus estimates
Maintain and communicate competitive intelligence and analysis on industry peers to leadership team
Act as a corporate liaison to institutional investors and sell-side analysts; provide accurate, consistent and timely responses to inquiries from investors and analysts.
Stay up-to-date with industry trends and best practices in communications and identify opportunities to apply new approaches within the company.
Champion Rocket’s mission, vision, values and behaviors.
Qualification
Find out how your skills align with this job's requirements. If anything seems off, you can easily click on the tags to select or unselect skills to reflect your actual expertise.
Required
BA or BS required in technical or science related degree; MBA or MD/PhD or other technical degree is a strong preference
8-10 years of relevant work experience in investment banking, equity research, investor relations, and/or corporate communications. Willing to consider a candidate with 5-8 years of experience with an advanced degree.
Knowledge of MS Office applications, especially good at Excel and PowerPoint.
Team player with flexibility to support important ad-hoc projects.
Strong written and verbal communication skills.
Outstanding communication skills and experience delivering clear messaging of scientific and clinical topics, as well as financial data, across a variety of audiences.
Strong attention to detail and ability to multi-task in a fast-paced, high-pressure, deadline driven environment.
Ability to interact with senior management and manage the communication of sensitive and confidential information.
Knowledge of SEC regulatory requirements and disclosures.
Proven ability to maintain and grow relationships with the investment community.
Excellent collaboration and interpersonal skills to work with others and integrate him/herself smoothly into the broader organization.
A desire to be part of a high-growth, transformational team.
Preferred
Experience in biotech, pharmaceuticals or healthcare strongly preferred.
Product launch experience in a publicly traded company is strongly preferred.
Benefits
Generous 401K match
Stock options
Excellent health benefits
Company
Rocket Pharmaceuticals
Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.
Funding
Current Stage
Public CompanyTotal Funding
$891.36MKey Investors
RTW InvestmentsCalifornia Institute for Regenerative Medicine
2023-09-12Post Ipo Equity· $175M
2022-10-03Post Ipo Equity· $100.3M
2021-08-30Post Ipo Equity· $26.4M
Recent News
2024-12-11
2024-12-11
2024-12-11
Company data provided by crunchbase